BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 8796144)

  • 1. Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas.
    Aguiar RC; Dahia PL; Sill H; Toledo SP; Goldman JM; Cross NC
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):93-6. PubMed ID: 8796144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
    J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.
    Benn DE; Croxson MS; Tucker K; Bambach CP; Richardson AL; Delbridge L; Pullan PT; Hammond J; Marsh DJ; Robinson BG
    Oncogene; 2003 Mar; 22(9):1358-64. PubMed ID: 12618761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population.
    Biden K; Young J; Buttenshaw R; Searle J; Cooksley G; Xu DB; Leggett B
    Hepatology; 1997 Mar; 25(3):593-7. PubMed ID: 9049204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis.
    Kawaguchi K; Oda Y; Saito T; Yamamoto H; Tamiya S; Takahira T; Miyajima K; Iwamoto Y; Tsuneyoshi M
    J Pathol; 2003 Nov; 201(3):487-95. PubMed ID: 14595762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of selected genes in neuroendocrine tumours: insulinomas and phaeochromocytomas.
    Hrasćan R; Pećina-Slaus N; Martić TN; Colić JF; Gall-Troselj K; Pavelić K; Karapandza N
    J Neuroendocrinol; 2008 Aug; 20(8):1015-22. PubMed ID: 18510707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan.
    Mangold KA; Takahashi H; Brandigi C; Wada T; Wakui S; Furusato M; Boyd J; Chandler FW; Allsbrook WC
    J Urol; 1997 Mar; 157(3):1117-20. PubMed ID: 9072554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas.
    Marchetti A; Buttitta F; Pellegrini S; Bertacca G; Chella A; Carnicelli V; Tognoni V; Filardo A; Angeletti CA; Bevilacqua G
    J Pathol; 1997 Feb; 181(2):178-82. PubMed ID: 9120722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
    Schmid M; Malicki D; Nobori T; Rosenbach MD; Campbell K; Carson DA; Carrera CJ
    Oncogene; 1998 Nov; 17(20):2669-75. PubMed ID: 9840931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
    Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
    J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation analysis of glial cell line-derived neurotrophic factor (GDNF), a ligand for the RET/GDNF receptor alpha complex, in sporadic phaeochromocytomas.
    Dahia PL; Toledo SP; Mulligan LM; Maher ER; Grossman AB; Eng C
    Cancer Res; 1997 Jan; 57(2):310-3. PubMed ID: 9000574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.
    García-Castellano JM; Villanueva A; Healey JH; Sowers R; Cordon-Cardo C; Huvos A; Bertino JR; Meyers P; Gorlick R
    Clin Cancer Res; 2002 Mar; 8(3):782-7. PubMed ID: 11895909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status.
    Chaussade L; Eymin B; Brambilla E; Gazzeri S
    Oncogene; 2001 Oct; 20(45):6587-96. PubMed ID: 11641784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of p16 genetic alterations in head and neck tumours.
    Miracca EC; Kowalski LP; Nagai MA
    Br J Cancer; 1999 Oct; 81(4):677-83. PubMed ID: 10574255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of novel germline deletions affecting SDHD and SDHC in pheochromocytoma and paraganglioma patients.
    Bayley JP; Weiss MM; Grimbergen A; van Brussel BT; Hes FJ; Jansen JC; Verhoef S; Devilee P; Corssmit EP; Vriends AH
    Endocr Relat Cancer; 2009 Sep; 16(3):929-37. PubMed ID: 19546167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent promoter methylation of tumor-related genes in sporadic and men2-associated pheochromocytomas.
    Dammann R; Schagdarsurengin U; Seidel C; Trümpler C; Hoang-Vu C; Gimm O; Dralle H; Pfeifer GP; Brauckhoff M
    Exp Clin Endocrinol Diabetes; 2005 Jan; 113(1):1-7. PubMed ID: 15662588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN gene loss, but not mutation, in benign and malignant phaeochromocytomas.
    van Nederveen FH; Perren A; Dannenberg H; Petri BJ; Dinjens WN; Komminoth P; de Krijger RR
    J Pathol; 2006 Jun; 209(2):274-80. PubMed ID: 16538614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.